GSK Announces Positive Phase III Results From Anchor Trials for Depemokimab in Chronic Rhinosinusitis With Nasal Polyps
October 15, 2024
October 15, 2024
LONDON, England, Oct. 15 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Oct. 14, 2024:
* * *
- Primary endpoints met with statistically significant reduction in nasal polyp size and nasal obstruction versus placebo plus standard of care, at 52 weeks
- Depemokimab is an ultra-long-acting biologic administered once every six months
- Patients with chronic rhinosinusitis with nasal pol . . .
* * *
- Primary endpoints met with statistically significant reduction in nasal polyp size and nasal obstruction versus placebo plus standard of care, at 52 weeks
- Depemokimab is an ultra-long-acting biologic administered once every six months
- Patients with chronic rhinosinusitis with nasal pol . . .